These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1592525)

  • 1. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis.
    Ceriani RL; Chan CM; Baratta FS; Ozzello L; DeRosa CM; Habif DV
    Int J Cancer; 1992 May; 51(3):343-54. PubMed ID: 1592525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast.
    Chan CM; Baratta FS; Ozzello L; Ceriani RL
    Breast Cancer Res Treat; 1994; 30(3):243-61. PubMed ID: 7981443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
    Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
    J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical study of Muc1, Muc2 and human gastric mucin in breast carcinoma: relationship with prognostic factors.
    Xu Y; Kimura N; Yoshida R; Lin H; Yoshinaga K
    Oncol Rep; 2001; 8(5):1177-82. PubMed ID: 11496338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate prognostic model for infiltrating ductal carcinoma of the breast in the axillary node-free patient.
    Ceriani RL; Baratta F; Gaslonde RJ; De Rosa CM; Ozzello L
    Adv Exp Med Biol; 1994; 353():155-67. PubMed ID: 7985534
    [No Abstract]   [Full Text] [Related]  

  • 7. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
    Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
    Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
    Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
    J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
    Chen Y; Song J; Jiang Y; Yu C; Ma Z
    Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of MUC1, MUC2 and oligosaccharide epitopes in breast cancer: prognostic significance of a sialylated MUC1 epitope.
    Baldus SE; Wienand JR; Werner JP; Landsberg S; Drebber U; Hanisch FG; Dienes HP
    Int J Oncol; 2005 Nov; 27(5):1289-97. PubMed ID: 16211224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size.
    Swede H; Moysich KB; Winston JS; Hurd TC; Edge SB; Romero-Gutierrez M; Brooks JS; Michalek AM
    Breast J; 2003; 9(2):98-105. PubMed ID: 12603382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
    Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
    Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma.
    Chia SK; Wykoff CC; Watson PH; Han C; Leek RD; Pastorek J; Gatter KC; Ratcliffe P; Harris AL
    J Clin Oncol; 2001 Aug; 19(16):3660-8. PubMed ID: 11504747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-phase fraction and nuclear size in long term prognosis of patients with breast cancer.
    Meyer JS; Province MA
    Cancer; 1994 Oct; 74(8):2287-99. PubMed ID: 7922981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group.
    Clark RM; Whelan T; Levine M; Roberts R; Willan A; McCulloch P; Lipa M; Wilkinson RH; Mahoney LJ
    J Natl Cancer Inst; 1996 Nov; 88(22):1659-64. PubMed ID: 8931610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and patient survival.
    Akslen LA; Varhaug JE
    Cancer; 1995 Nov; 76(9):1643-54. PubMed ID: 8635070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.